mdxhealth posted fourth-quarter revenue of $29.5 million, up 19% year over year, and full-year 2025 revenue of $107.9 million, up 20%. Gross margin expanded to 64.5% for the year, and adjusted EBITDA narrowed to a $1.1 million loss, approaching breakeven. The company reaffirmed 2026 guidance of $137–140 million in revenue, implying 27–30% growth, and targets a 10% adjusted EBITDA margin run rate exiting next year. The mix is shifting quickly: in Q4, liquid-based assays nearly doubled volumes year over year while tissue-based test volumes declined, and liquid tests now account for a larger slice of revenue than a year ago.
The strategic signal is clear: a urology diagnostics player long anchored in tissue-based assays is leaning into an earlier, less invasive entry point in the prostate cancer pathway. The bet is that scaling pre-biopsy liquid tests will widen funnel reach, seed downstream demand for confirmatory and prognostic tissue assays, and deliver operating leverage across a single commercial and lab platform. The open question is whether payer coverage, coding stability, and average selling prices for early-pathway liquid diagnostics can sustain the margin narrative the company is now guiding toward.
For patients and urologists, the growth of liquid diagnostics can reduce unnecessary biopsies and overtreatment by sharpening decision points earlier in the journey. That shifts clinic workflow and may compress interventional volumes while enriching risk stratification for those who proceed. Payers are likely receptive to rule-out value propositions that avert procedures and downstream costs, but claims adjudication in molecular diagnostics remains volatile. Real-world evidence tying these tests to reduced biopsy rates, fewer complications, and preserved outcomes will be decisive for broad commercial coverage and consistent collections. For hospital systems and independent practices, the expanding menu—spanning pre-biopsy liquid tests, post-negative biopsy tissue assays, and prognostic scoring—creates an opportunity to standardize pathways, but also a need for education and utilization governance to align with local coverage determinations.
Competitively, the company is positioning a full-pathway approach against single-modality rivals in prostate cancer genomics. The aim mirrors broader diagnostics consolidation: assemble multi-modality menus, leverage one field force, drive higher account penetration, and smooth revenue cycles across referral peaks and troughs. In prostate cancer specifically, diagnostic decisions increasingly influence therapy markets—from active surveillance versus early intervention to germline and genomic stratification that informs use of PARP inhibitors, radioligand therapies, and intensified androgen pathway regimens. Biopharma teams in urologic oncology should view this diagnostic expansion as both a market-shaping force and a collaboration vector for outcomes-linked evidence generation.
Beneath the growth, the balance sheet sets the execution bar high. Year-end cash stood at $29.0 million with a full-year net loss of $33.5 million, rising interest expense, and a shareholders’ deficit on the statement of financial position. Operating expenses rose with recent acquisitions, and contingent financial liabilities remain material. Hitting 2026 guidance will require converting higher liquid-test volumes into durable reimbursement, accelerating cash collections, and maintaining gross margin gains from fixed-cost absorption while tamping operating spend.
The industry trend line favors integrated diagnostics platforms that can prove utility with real-world data and translate scale into profitability. The next twelve months will test whether a liquid-led funnel can power a profitable urology diagnostics franchise. Watch for payer policy updates, ASP stability, cross-sell uptake from liquid to tissue tests, and evidence packages tying diagnostic choices to procedure avoidance and oncologic outcomes. If those levers move in tandem, the pathway strategy could become a template for specialty diagnostics. If not, rising financing costs may force another round of portfolio and cost resets.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
